Friday, January 17, 2025 3:45:51 PM
What i don't get is why, why, and why the HUGE connection
to Canada with this research?? https://experts.mcmaster.ca/display/gstein
Has this publication https://www.cell.com/cell-reports-medicine/fulltext/S2666-3791(23)00360-9
been debated to death on st already, if it has i completely missed that on st.
Yes it is from November '23, not exactly new but in publication world not that old either.
This is huge and is a good indication into what that liver indication and trial is about.
That's where i see NVO as a solid possible partner for US/Canada BA sales and the also being a liver trial partner to boot.
Does this make sense or have i lost it here on a friday afternoon.
more info next post
to Canada with this research?? https://experts.mcmaster.ca/display/gstein
Has this publication https://www.cell.com/cell-reports-medicine/fulltext/S2666-3791(23)00360-9
been debated to death on st already, if it has i completely missed that on st.
Yes it is from November '23, not exactly new but in publication world not that old either.
This is huge and is a good indication into what that liver indication and trial is about.
That's where i see NVO as a solid possible partner for US/Canada BA sales and the also being a liver trial partner to boot.
Does this make sense or have i lost it here on a friday afternoon.
more info next post
Recent ESPR News
- Form 8-K - Current report • Edgar (US Regulatory) • 04/02/2026 08:22:14 PM
- Athyrium Capital Management and Esperion Enter Into $50 Million Japan Royalty Financing to Support Strategic Acquisition of Corstasis Therapeutics • GlobeNewswire Inc. • 04/02/2026 08:05:00 PM
- Esperion Therapeutics Closes Acquisition of Corstasis Therapeutics, Expanding Its Cardiovascular Franchise with Enbumyst™ (bumetanide nasal spray) • GlobeNewswire Inc. • 04/02/2026 08:00:00 PM
- Esperion to Participate in 25th Annual Needham Virtual Healthcare Conference • GlobeNewswire Inc. • 03/31/2026 12:00:00 PM
- Esperion Showcases New Data from CLEAR Outcomes Highlighting Value of NEXLETOL® (bempedoic acid) at the American College of Cardiology’s Annual Scientific Session 2026 • GlobeNewswire Inc. • 03/30/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/18/2026 08:13:45 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/18/2026 08:13:23 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/18/2026 08:12:52 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/17/2026 07:19:46 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/17/2026 07:17:35 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/17/2026 07:12:41 PM
- Esperion to Present Two New Analyses from CLEAR Outcomes Clinical Trial at the American College of Cardiology 2026 Annual Scientific Session • GlobeNewswire Inc. • 03/17/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/16/2026 08:20:52 PM
- Esperion’s Bempedoic Acid Receives Multiple Class 1 Recommendations in 2026 ACC/AHA Multisociety Guideline for Management of Dyslipidemia • GlobeNewswire Inc. • 03/16/2026 10:30:00 AM
- Esperion shares rise 8% after revenue tops forecasts and acquisition announced • IH Market News • 03/10/2026 12:56:39 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/10/2026 11:17:29 AM
- Esperion Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update • GlobeNewswire Inc. • 03/10/2026 10:00:00 AM
- /C O R R E C T I O N -- HLS Therapeutics Inc./ • PR Newswire (Canada) • 03/05/2026 01:55:00 PM
- HLS Therapeutics Announces NILEMDOTM (bempedoic acid) is now available in Canada for the Reduction of LDL-Cholesterol in Patients at Risk of Cardiovascular Disease • PR Newswire (Canada) • 03/05/2026 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/03/2026 12:03:05 PM
- Esperion Therapeutics and Corstasis Therapeutics Announce Esperion’s Definitive Agreement to Acquire Corstasis, Expanding Its Cardiovascular Franchise with Enbumyst™ (bumetanide nasal spray) • GlobeNewswire Inc. • 03/03/2026 11:00:00 AM
- Esperion Therapeutics and Corstasis Therapeutics Announce Esperion’s Definitive Agreement to Acquire Corstasis, Expanding Its Cardiovascular Franchise with Enbumyst™ (bumetanide nasal spray) • Business Wire • 03/03/2026 11:00:00 AM
- Esperion to Report Fourth Quarter and Full Year 2025 Financial Results on March 10 • GlobeNewswire Inc. • 02/24/2026 01:00:00 PM
- Esperion to Participate in The 2026 Citizens Life Sciences Conference • GlobeNewswire Inc. • 02/18/2026 01:00:00 PM
- Esperion Reaches Settlement Agreement with Fifth ANDA Filer Not to Market Generic Version of NEXLETOL® (bempedoic acid) & NEXLIZET® (bempedoic acid & ezetimibe) Prior to April 19, 2040 • GlobeNewswire Inc. • 02/17/2026 01:00:00 PM
